News
-
-
PRESS RELEASE
#FutureFresenius: REJUVENATE in action – Delivering accelerated performance for long-term value creation; 2025 yet another year of strong delivery
Fresenius SE & Co. KGaA reports strong FY/25 results with 7% organic revenue growth and 12% Core EPS growth. Improved EBIT margin and increased dividend proposal. #FutureFresenius strategy aims for sustainable growth -
-
PRESS RELEASE
Fresenius Supervisory Board extends ahead of schedule CEO Michael Sen’s contract by five years --- Christian Pawlu to join Management Board for Fresenius Helios effective July 1, 2026
Fresenius extends CEO Michael Sen's contract by 5 years and appoints Christian Pawlu to Management Board effective July 1, 2026, ensuring continuity and strategic leadership for #FutureFresenius. Dr. Pawlu to oversee Fresenius Helios operations replacing Robert Möller -
-
PRESS RELEASE
EQS-Adhoc: Fresenius SE & Co. KGaA: Fresenius announces its intention to reduce its stake in Fresenius Medical Care AG from currently around 32.2% to no less than 25% plus one share
Fresenius SE & Co. KGaA announces intention to reduce stake in Fresenius Medical Care AG to at least 25% plus one share, aiming to strengthen balance sheet and deliver long-term growth -
-
-
-
